Plasma biomarker analysis in pediatric ARDS: generating future framework from a pilot randomized control trial of methylprednisoloneA framework for identifying plasma biomarkers related to clinical outcomes in pediatric ARDS
Objective: Lung injury activates multiple pro-inflammatory pathways, including neutrophils, epithelial and endothelial injury, and coagulation factors leading to acute respiratory distress syndrome (ARDS). Low-dose methylprednisolone therapy (MPT) improved oxygenation and ventilation in early pedia...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-03-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fped.2016.00031/full |
| _version_ | 1818320695609786368 |
|---|---|
| author | Dai eKimura Dai eKimura Jordy eSaravia Jordy eSaravia Cynthia R Rovnaghi Gianfranco Umberto Meduri Gianfranco Umberto Meduri Andreas eSchwingshackl Stephania eCormier Stephania eCormier Kanwaljeet J. S. Anand |
| author_facet | Dai eKimura Dai eKimura Jordy eSaravia Jordy eSaravia Cynthia R Rovnaghi Gianfranco Umberto Meduri Gianfranco Umberto Meduri Andreas eSchwingshackl Stephania eCormier Stephania eCormier Kanwaljeet J. S. Anand |
| author_sort | Dai eKimura |
| collection | DOAJ |
| description | Objective: Lung injury activates multiple pro-inflammatory pathways, including neutrophils, epithelial and endothelial injury, and coagulation factors leading to acute respiratory distress syndrome (ARDS). Low-dose methylprednisolone therapy (MPT) improved oxygenation and ventilation in early pediatric ARDS without altering duration of mechanical ventilation or mortality. We evaluated the effects of MPT on biomarkers of endothelial (Ang-2, sICAM-1) or epithelial (sRAGE) injury, neutrophil activation (MMP-8), and coagulation (PAI-1). Design: Double-blind, placebo-controlled randomized trialSetting: Tertiary-care Pediatric Intensive Care Unit Patients: Mechanically ventilated children (0-18 years) with early ARDS.Interventions: Blood samples were collected on Days 0 (before MPT), 7, and 14 during low-dose MPT (n=17) vs. placebo (n=18) therapy. The MPT group received a 2mg/kg loading dose followed by 1mg/kg/day continuous infusions from days 1-7, tapered off over 7 days; placebo group received equivalent amounts of 0.9% saline. We analyzed plasma samples using a multiplex assay for 5 biomarkers of ARDS. Multiple regression models were constructed to predict associations between changes in biomarkers and the clinical outcomes reported earlier including: P/F ratio on days 8&9, plateau pressure on days 1&2, PaCO2 on days 2&3, racemic epinephrine following extubation, and supplemental oxygen at ICU discharge.Results: No differences occurred in biomarker concentrations between the groups on Day 0. On Day 7, reduction in MMP-8 levels (p=0.0016) occurred in the MPT group, whereas increases in sICAM-1 levels (p=0.0005) occurred in the placebo group (no increases in sICAM-1 in the MPT group). sRAGE levels decreased in both MPT and placebo groups (p<0.0001) from Day 0 to Day 7. On Day 7, sRAGE levels were positively correlated with MPT group PaO2/FiO2 ratios on Day 8 (r=0.93, p=0.024). O2 requirements at ICU transfer positively correlated with Day 7 MMP-8 (r=0.85, p=0.016) and Ang-2 levels (r=0.79, p=0.036) in the placebo group, and inversely correlated with Day 7 sICAM-1 levels (r=-0.91, p=0.005) in the MPT group.Conclusion: Biomarkers selected from endothelial, epithelial, or intravascular factors can be correlated with clinical endpoints in pediatric ARDS. For example, MPT could reduce neutrophil activation (MMP-8), decrease endothelial injury (sICAM-1) and allow epithelial recovery (sRAGE). Large ARDS clinical trials should develop similar frameworks. |
| first_indexed | 2024-12-13T10:29:06Z |
| format | Article |
| id | doaj.art-2cfadbf5cfb54235b3589c5731090672 |
| institution | Directory Open Access Journal |
| issn | 2296-2360 |
| language | English |
| last_indexed | 2024-12-13T10:29:06Z |
| publishDate | 2016-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj.art-2cfadbf5cfb54235b3589c57310906722022-12-21T23:50:54ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602016-03-01410.3389/fped.2016.00031184432Plasma biomarker analysis in pediatric ARDS: generating future framework from a pilot randomized control trial of methylprednisoloneA framework for identifying plasma biomarkers related to clinical outcomes in pediatric ARDSDai eKimura0Dai eKimura1Jordy eSaravia2Jordy eSaravia3Cynthia R Rovnaghi4Gianfranco Umberto Meduri5Gianfranco Umberto Meduri6Andreas eSchwingshackl7Stephania eCormier8Stephania eCormier9Kanwaljeet J. S. Anand10University of Tennessee Health Science CenterChildren’s Foundation Research Institute at Le Bonheur Children’s HospitalUniversity of Tennessee Health Science CenterChildren’s Foundation Research Institute at Le Bonheur Children’s HospitalStanford UniversityUniversity of Tennessee Health Science CenterVeteran’s Affair Medical CenterUniversity of California Los AngelesChildren’s Foundation Research Institute at Le Bonheur Children’s HospitalUniversity of Tennessee Health Science CenterStanford University School of MedicineObjective: Lung injury activates multiple pro-inflammatory pathways, including neutrophils, epithelial and endothelial injury, and coagulation factors leading to acute respiratory distress syndrome (ARDS). Low-dose methylprednisolone therapy (MPT) improved oxygenation and ventilation in early pediatric ARDS without altering duration of mechanical ventilation or mortality. We evaluated the effects of MPT on biomarkers of endothelial (Ang-2, sICAM-1) or epithelial (sRAGE) injury, neutrophil activation (MMP-8), and coagulation (PAI-1). Design: Double-blind, placebo-controlled randomized trialSetting: Tertiary-care Pediatric Intensive Care Unit Patients: Mechanically ventilated children (0-18 years) with early ARDS.Interventions: Blood samples were collected on Days 0 (before MPT), 7, and 14 during low-dose MPT (n=17) vs. placebo (n=18) therapy. The MPT group received a 2mg/kg loading dose followed by 1mg/kg/day continuous infusions from days 1-7, tapered off over 7 days; placebo group received equivalent amounts of 0.9% saline. We analyzed plasma samples using a multiplex assay for 5 biomarkers of ARDS. Multiple regression models were constructed to predict associations between changes in biomarkers and the clinical outcomes reported earlier including: P/F ratio on days 8&9, plateau pressure on days 1&2, PaCO2 on days 2&3, racemic epinephrine following extubation, and supplemental oxygen at ICU discharge.Results: No differences occurred in biomarker concentrations between the groups on Day 0. On Day 7, reduction in MMP-8 levels (p=0.0016) occurred in the MPT group, whereas increases in sICAM-1 levels (p=0.0005) occurred in the placebo group (no increases in sICAM-1 in the MPT group). sRAGE levels decreased in both MPT and placebo groups (p<0.0001) from Day 0 to Day 7. On Day 7, sRAGE levels were positively correlated with MPT group PaO2/FiO2 ratios on Day 8 (r=0.93, p=0.024). O2 requirements at ICU transfer positively correlated with Day 7 MMP-8 (r=0.85, p=0.016) and Ang-2 levels (r=0.79, p=0.036) in the placebo group, and inversely correlated with Day 7 sICAM-1 levels (r=-0.91, p=0.005) in the MPT group.Conclusion: Biomarkers selected from endothelial, epithelial, or intravascular factors can be correlated with clinical endpoints in pediatric ARDS. For example, MPT could reduce neutrophil activation (MMP-8), decrease endothelial injury (sICAM-1) and allow epithelial recovery (sRAGE). Large ARDS clinical trials should develop similar frameworks.http://journal.frontiersin.org/Journal/10.3389/fped.2016.00031/fullLung InjuryMethylprednisoloneSteroidsbiomarkerICAM-1pediatric |
| spellingShingle | Dai eKimura Dai eKimura Jordy eSaravia Jordy eSaravia Cynthia R Rovnaghi Gianfranco Umberto Meduri Gianfranco Umberto Meduri Andreas eSchwingshackl Stephania eCormier Stephania eCormier Kanwaljeet J. S. Anand Plasma biomarker analysis in pediatric ARDS: generating future framework from a pilot randomized control trial of methylprednisoloneA framework for identifying plasma biomarkers related to clinical outcomes in pediatric ARDS Frontiers in Pediatrics Lung Injury Methylprednisolone Steroids biomarker ICAM-1 pediatric |
| title | Plasma biomarker analysis in pediatric ARDS: generating future framework from a pilot randomized control trial of methylprednisoloneA framework for identifying plasma biomarkers related to clinical outcomes in pediatric ARDS |
| title_full | Plasma biomarker analysis in pediatric ARDS: generating future framework from a pilot randomized control trial of methylprednisoloneA framework for identifying plasma biomarkers related to clinical outcomes in pediatric ARDS |
| title_fullStr | Plasma biomarker analysis in pediatric ARDS: generating future framework from a pilot randomized control trial of methylprednisoloneA framework for identifying plasma biomarkers related to clinical outcomes in pediatric ARDS |
| title_full_unstemmed | Plasma biomarker analysis in pediatric ARDS: generating future framework from a pilot randomized control trial of methylprednisoloneA framework for identifying plasma biomarkers related to clinical outcomes in pediatric ARDS |
| title_short | Plasma biomarker analysis in pediatric ARDS: generating future framework from a pilot randomized control trial of methylprednisoloneA framework for identifying plasma biomarkers related to clinical outcomes in pediatric ARDS |
| title_sort | plasma biomarker analysis in pediatric ards generating future framework from a pilot randomized control trial of methylprednisolonea framework for identifying plasma biomarkers related to clinical outcomes in pediatric ards |
| topic | Lung Injury Methylprednisolone Steroids biomarker ICAM-1 pediatric |
| url | http://journal.frontiersin.org/Journal/10.3389/fped.2016.00031/full |
| work_keys_str_mv | AT daiekimura plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT daiekimura plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT jordyesaravia plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT jordyesaravia plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT cynthiarrovnaghi plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT gianfrancoumbertomeduri plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT gianfrancoumbertomeduri plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT andreaseschwingshackl plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT stephaniaecormier plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT stephaniaecormier plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards AT kanwaljeetjsanand plasmabiomarkeranalysisinpediatricardsgeneratingfutureframeworkfromapilotrandomizedcontroltrialofmethylprednisoloneaframeworkforidentifyingplasmabiomarkersrelatedtoclinicaloutcomesinpediatricards |